A 4-week maximum-dose PRN PDE5I run-in was followed by a 4-week nondrug washout period , then randomization to tadalafil 2.5 mg titrated to 5 mg or tadalafil 5 mg ( pooled for analyses ) or placebo once daily for 12 weeks .